{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:42:10Z","timestamp":1793284930630,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.resinv.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T17:51:37Z","timestamp":1561398697000},"page":"451-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer"],"prefix":"10.1016","volume":"57","author":[{"given":"Yu","family":"Nakanishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kakuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinjiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Horimasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Fujitaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihito","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2019.05.002_bib1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2019.05.002_bib2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2019.05.002_bib3","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2019.05.002_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Eng J Med"},{"key":"10.1016\/j.resinv.2019.05.002_bib5","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2019.05.002_bib6","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.resinv.2019.05.002_bib7","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res\u202f"},{"key":"10.1016\/j.resinv.2019.05.002_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2019.05.002_bib9","doi-asserted-by":"crossref","first-page":"44173","DOI":"10.1038\/srep44173","article-title":"PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2019.05.002_bib10","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/JTO.0b013e318216ee6b","article-title":"The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer","volume":"6","author":"Kenmotsu","year":"2011","journal-title":"J Thorac Onco"},{"key":"10.1016\/j.resinv.2019.05.002_bib11","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2019.05.002_bib12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.lungcan.2018.10.001","article-title":"Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis","volume":"125","author":"Yamaguchi","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2019.05.002_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1759-7714.12759","article-title":"Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease","volume":"9","author":"Kanai","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.resinv.2019.05.002_bib14","first-page":"998","article-title":"Interstitial lung abnormalities in treatment-na\u00efve advanced non-small-cell lung cancer patients are associated with shorter survival","volume":"84","author":"Nishino","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2019.05.002_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.acra.2009.07.016","article-title":"Identification of early interstitial lung disease in smokers from the COPDGene Study","volume":"17","author":"Washko","year":"2010","journal-title":"Acad Radiol"},{"key":"10.1016\/j.resinv.2019.05.002_bib16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJMoa1007285","article-title":"Lung volumes and emphysema in smokers with interstitial lung abnormalities","volume":"364","author":"Washko","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2019.05.002_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.200611-1696OC","article-title":"Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival","volume":"177","author":"Sumikawa","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2019.05.002_bib18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2019.05.002_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-017-3476-5","article-title":"The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer","volume":"81","author":"Masuda","year":"2018","journal-title":"Cancer Chemothera Pharmacol"},{"key":"10.1016\/j.resinv.2019.05.002_bib20","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/thx.47.12.1064","article-title":"New perspectives on basic mechanisms in lung disease. 1. Lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis","volume":"47","author":"Sheppard","year":"1992","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2019.05.002_bib21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00595-010-4384-z","article-title":"Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography","volume":"41","author":"Suzuki","year":"2011","journal-title":"Surg Today"},{"key":"10.1016\/j.resinv.2019.05.002_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","article-title":"A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia","volume":"111","author":"Fujimoto","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2019.05.002_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.1579","article-title":"Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: A case-control study","author":"Cui","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.resinv.2019.05.002_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534519300188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534519300188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T13:34:56Z","timestamp":1566999296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534519300188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2212534519300188"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2019.05.002","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}